In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation announced that it has appointed Aaron Berg, currently Amarin’s executive vice president and president of the US business, as president and chief executive (CEO). 5 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Shares in California, USA-based autoimmune specialist Annexon soared more than 37% in pre-market trading on Tuesday to $6.32, after it announced positive top-line results from its randomized placebo-controlled pivotal Phase III trial in patients with Guillain-Barré syndrome (GBS). 5 June 2024
Pharmaceutical
San Diego, USA-based biopharma company Viking Therapeutics has announced favorable 52-week results from its Phase IIb VOYAGE study of VK2809. 5 June 2024
Biotechnology
Florida, USA-based Summit Therapeutics has managed to beat the leading checkpoint blocker, Keytruda (pembrolizumab), in a head-to-head comparison. 4 June 2024
Pharmaceutical
Japanese pharma major Takeda has presented positive results from its Phase IIb trial of TAK-861 at the SLEEP 2024 annual meeting. 4 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
The market for branded multiple myeloma drugs is projected to grow to $33 billion by 2030, up from $23.5 billion in 2023, according to Bloomberg Intelligence (BI). 4 June 2024
Biotechnology
BridgeBio Pharma’s (Nasdaq: BBIO) shares were up nearly 5% at $30.37 in early trading, after the company announced sustained positive results from PROPEL 2. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Generics
India has become the largest supplier of drugs to the Russian market, overtaking Germany, which had been in the lead for the last two years, reports The Pharma Letter’s Russia correspondent. 4 June 2024
Biotechnology
Shares of US biotech Structure Therapeutics shot up as much as 71% yesterday and gained a further 4.6% to $55.17 in pre-market activity on the back of encouraging research results on its oral GLP-1 weight management candidate. 4 June 2024
Pharmaceutical
Japanese pharma major Shionogi says it is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in San Diego, California, USA. 4 June 2024
Pharmaceutical
UK drugmaker GSK closed 9% lower after Monday’s trading in London on news of a negative court ruling. 4 June 2024
Pharmaceutical
The attention-deficit/hyperactivity disorder (ADHD) market across the seven major markets (7MM) is forecast to decline at a negative compound annual growth rate (CAGR) of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032. 4 June 2024
Biotechnology
Israel-based artificial intelligence (AI) focused biotech Biolojic Design has entered into a multi-target drug discovery collaboration with Germany’s Merck KGaA. 4 June 2024
Pharmaceutical
Bladder cancer specialist UroGen Pharma has appointed David Lin as chief commercial officer. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Biotechnology
While cancer-focused pharma and biotech are busy presenting their latest research achievements at the ongoing American Society of Clinical Oncology (ASCO) meeting, Germany’s Merck KGaA also held its own Oncology R&D Update Call. 3 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze